Clinical Trial Update: Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating peptide receptor radionuclide therapy for advanced, non-resectable or symptomatic tumors with SSTR overexpression in neuroendo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Snippet

Sponsor: University of Warmia and Mazury | Conditions: Neuroendocrine Tumors | Phase 2 | Status: UNKNOWN